Kamada discontinues Phase 3 inhaled AAT trial after futility analysis
Tweet Send to a Friend
Kamada Ltd. (NASDAQ: KMDA) announced the discontinuation of its Phase 3 InnovAATe trial for inhaled alpha-1 antitrypsin (AAT) treatment following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
